Home・Stock List・Legend Biotech Corp ADR

Legend Biotech Corp ADR

Closed

SectorHealthcare

19.11 1.16

Buy Sell

Overview

Share price change

24h

Current

Min

18.8

Max

19.34

Key metrics
By Trading Economics
Income	-24M -54M
Sales	-2.5M 305M
EPS	-0.15
Profit margin	-17.851
Employees	3,100
EBITDA	-24M -32M

Recommendations
By TipRanks
Recommendations	Buy
12 Months Forecast	+175.38% upside

Dividends
By Acuity
Next Earnings	11 Aug 2026

Market Stats
By TradingEconomics
Market Cap	-1B 3.7B
Previous open	17.95
Previous close	19.11

News Sentiment

By Acuity

100%

320 / 340 Healthcare

Legend Biotech Corp ADR Chart

Past performance is not a reliable indicator of future results.

Related News

3 Aug 2026, 22:01 UTC

Shares of Legend Biotech Corp are higher in after-market trading, reflecting gains since Monday's close amid broader market advances in tech and oil-sensitive sectors.

31 Jul 2026, 23:56 UTC

Shares of Legend Biotech Corp. are higher in after-market trading, despite a slight decline earlier in the session and broader market weakness.

30 Jul 2026, 22:41 UTC

Shares of Legend Biotech Corp are trading lower in after-market hours, continuing a trend of unusual weakness since Thursday's close.

29 Jul 2026, 19:27 UTC

Social Media

Legend Biotech Corp shares are lower, extending a four-session decline. Raymond James projects a 12-month price target range of $58 to $86.

28 Jul 2026, 22:56 UTC

Shares of Legend Biotech Corp are trading higher in after-market hours, despite no specific news identified. The broader market showed gains earlier in the day.

27 Jul 2026, 23:16 UTC

Legend Biotech Corp shares are higher in after-market hours, having briefly reached a session high. The price remains below its 20-day moving average.

24 Jul 2026, 19:16 UTC

News

UBS downgraded Legend Biotech Corp to Neutral and cut its price target to $28, contributing to a decline in shares during Friday's session.

22 Jul 2026, 18:31 UTC

Legend Biotech Corp shares are lower today amid broader market weakness and rising geopolitical tensions, despite an earlier peak during the session.

21 Jul 2026, 16:46 UTC

Legend Biotech Corp. shares are higher today, reaching a session peak amid rising crude oil prices, despite trading below its 20-day moving average.

20 Jul 2026, 19:01 UTC

Legend Biotech Corp is trading higher during Monday's session, rebounding from an earlier low and showing strength after a week of declines.

Peer Comparison

Price change

Legend Biotech Corp ADR Forecast

Price Target

By TipRanks

175.38% upside

12 Months Forecast

Average 52.35 USD 175.38%

High 80 USD

Low 28 USD

Based on 10 Wall Street analysts offering 12 month price targets forLegend Biotech Corp ADR - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

10 ratings

Buy

Hold

Sell

Based on 10 analysts giving stock ratings to Legend Biotech Corp ADR - Dist in the past 3 months.

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Legend Biotech Corp ADR

Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. The company was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation operates as a subsidiary of Genscript Biotech Corporation.